Cingulate logo

CingulateNASDAQ: CING

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

08 December 2021

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$14.39 M
-71%vs. 3y high
21%vs. sector
-vs. 3y high
-vs. sector
-99%vs. 3y high
43%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | 4 min ago
$4.48+$0.48(+12.00%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

CING Latest News

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301
globenewswire.com12 September 2024 Sentiment: POSITIVE

$10 Million of additional Capital Recently Raised Strengthening Balance Sheet $10 Million of additional Capital Recently Raised Strengthening Balance Sheet

Cingulate to Participate in Benzinga All Live Access Event
globenewswire.com27 August 2024 Sentiment: POSITIVE

KANSAS CITY, Kan., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer, PharmD, will participate in a live Benzinga All Access event on August 28, 2024, at 10:30 a.m. CST.

Cingulate Announces Adjournment of Special Meeting
globenewswire.com23 August 2024 Sentiment: NEUTRAL

KANSAS CITY, Kan., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), (“Cingulate” or the “Company”), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that it has adjourned its Special Meeting of Stockholders (the “Special Meeting”) in order to provide stockholders additional time within which to vote on all proposals.

FLEX Coin struggles as CoinFLEX creditors woes worsen after OPNX closure
invezz.com16 August 2024 Sentiment: NEGATIVE

In recent months, FLEX Coin has experienced significant price volatility, reflecting broader turbulence within its parent platform, CoinFLEX. The token, which had reached an all-time high of $8.16 in August 2023, has since plunged by over 90%, currently trading around $0.71.

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD
globenewswire.com15 August 2024 Sentiment: POSITIVE

KANSAS CITY, Kan., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it was issued a European patent for its lead asset CTx-1301 (dexmethylphenidate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds
globenewswire.com28 June 2024 Sentiment: POSITIVE

KANSAS CITY, Kan., June 28, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (the “Company”) (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the entry into definitive agreements for the immediate exercise of certain outstanding Series A warrants to purchase up to an aggregate of 2,125,000 shares of common stock of the Company and Series B warrants to purchase up to an aggregate of 1,062,500 shares of common stock of the Company originally issued in February 2023, having an exercise price of $2.00 per share, at a reduced exercise price of $0.585 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-276502). The offering is expected to close on or about July 1, 2024, subject to satisfaction of customary closing conditions.

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event
globenewswire.com25 June 2024 Sentiment: POSITIVE

KANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer, PharmD, and preeminent board-certified psychiatrist and Cingulate scientific advisor Dr. Ann Childress, MD, will participate in a live Benzinga All Access event on June 26, 2024, at 10:30 a.m. CST.

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance
globenewswire.com25 June 2024 Sentiment: POSITIVE

Twelve Required Registration Batches Completed New Drug Application Being Prepped for Submission KANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) -- In alignment with U.S. Food and Drug Administration (FDA) requirements, Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has completed the manufacturing of its twelve registration batches for its lead asset CTx-1301 (dexmethylphenidate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Why Is Cingulate (CING) Stock Up 160% Today?
InvestorPlace28 December 2023 Sentiment: POSITIVE

Cingulate (NASDAQ: CING ) stock is soaring over 160% in early trading and trending on many financial news websites. The rally was sparked by the company's announcement that the Nasdaq exchange would postpone delisting its shares for several weeks.

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing
Market Watch28 December 2023 Sentiment: POSITIVE

Shares of Cingulate Inc. CING, +101.52% blasted 226.3% higher in premarket trading Thursday after the biopharmaceutical company disclosed that the delisting of its stock has been delayed until at least February. After closing Tuesday at a record low of $1.98, the stock had soared a record 101.5% on Wednesday.

What type of business is Cingulate?

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

What sector is Cingulate in?

Cingulate is in the Healthcare sector

What industry is Cingulate in?

Cingulate is in the Biotechnology industry

What country is Cingulate from?

Cingulate is headquartered in United States

When did Cingulate go public?

Cingulate initial public offering (IPO) was on 08 December 2021

What is Cingulate website?

https://www.cingulate.com

Is Cingulate in the S&P 500?

No, Cingulate is not included in the S&P 500 index

Is Cingulate in the NASDAQ 100?

No, Cingulate is not included in the NASDAQ 100 index

Is Cingulate in the Dow Jones?

No, Cingulate is not included in the Dow Jones index

When was Cingulate the previous earnings report?

No data

When does Cingulate earnings report?

Next earnings report date is not announced yet